Open AccessFormulation, Optimization and In-vitro Evaluation of Fast Dissolving Oral films of Metoclopramide Hydrochloride by Solvent Casting method
Author(s) -
Chandrajeet Kumar Yadav,
Manish Karn,
Pinki Yadav,
Roshan Kumar Mehta
Publication year - 2020
Publication title -
international journal of pharmtech research
Language(s) - English
Resource type - Journals
eISSN - 2455-9563
pISSN - 0974-4304
DOI - 10.20902/ijptr.2019.130314
Subject(s) - dissolution , dosage form , bioavailability , solvent , chromatography , plasticizer , chemistry , materials science , polymer , pharmaceutics , nuclear chemistry , pharmacology , organic chemistry , medicine
The Present study aimed to prepare fast dissolving oral films (FDFs) ofmetoclopramide hydrochloride, because of its application in emesis condition where fast onsetof action and avoidance of water is highly desirable. Moreover, this dosage form is highlyuseful in pediatrics, geriatrics and unconscious patients. FDFs were prepared by solventcasting technique with film forming polymers HPMC, PVA & Sodium alginate in varyingconcentrations with excipients like SLS as surfactant, Glycerol as plasticizer, citric acid assaliva stimulating agent, Sodium Saccharin as sweetening agent. The film of 2×3 cm wasprepared by casting into a petridish of calculated size and dried in dryer at temperature 40˚c.The In-Vitro evaluation of characteristics like Film Thickness, Weight Variation,disintegration time, dissolution study, surface pH, content uniformity was studied. The bestformulation was found to be F5 containing polymer PVA and Sodium alginate in the ratio 2:1,with disintegration time 24 seconds, and dissolution profile of 75% in 60 seconds and 90% in90 seconds. The content uniformity of all the formulations was found to be within the limit(98-101%). The disintegration time of all the formulations was found to be below 30 secondsexcept F4 (26 sec.). Thus, fast dissolving Films of Metoclopramide hydrochloride can besuccessfully formulated and will be used as a novel drug dosage form for paediatric andgeriatric with improved patient compliance and enhanced bioavailability.